



Scientific Committee on Consumer Safety (SCCS) WG on Methodologies

Venue: Luxembourg

Meeting date: 21 May 2014

Minutes

1. WELCOME AND APOLOGIES

The Chair welcomed the participants and announced four apologies. Cosmetics Europe (CoE) was invited to participate, as contributor, to the dedicated morning session on bioavailability correction factor of the oral NOAEL and the development of a modified reduced MTT in in vitro irritation test method.

2. ADOPTION OF THE AGENDA

The agenda was adopted as presented.

3. DECLARATION OF INTEREST ON MATTERS ON THE AGENDA

No declaration of potential conflict of interest was made by the members of the WG.

4. PRESENTATIONS

- Follow-up of Low Bioavailability: a presentation of new data from the SCCS Database was made by Vera Rogiers and impact on potential changes of the Notes of Guidance (NoG) was discussed.
- Bioavailability Correction Factor of the oral NOAEL: Dagmar Bury, L'Oréal, representing CoE made a presentation that was followed by a discussion.
- Use of HPLC for Detection of reduced MTT in in vitro irritation test methods based on reconstructed human tissue for assessment of intrinsically coloured test materials: A presentation was made by Nathalie Alepée, L'Oréal, representing CoE, and a discussion followed.

5. INTERNAL MEETING OF THE WG METHODOLOGIES

- Information from Chair/Members/Commission: The Chair informed about a workshop that took place 29-30 April 2014 as part of the EU ongoing project SEURAT-1 on read-across and chemical grouping approaches. The Secretariat informed about a joint meeting of ESTAF and PARERE which

will take place on 5-6 June. The WG agreed on sending an observer.

- The group discussed the way forward according to the morning presentations and discussions.
- Follow-up BMD approach: Following the previous WG meeting (28/3), SCCS and EFSA exchanged points of views. EFSA will set a new WG to update their approach to the benchmark dose from summer 2014 which is helpful for collaboration and bilateral discussion. In addition, a SCCS representative may be invited.
- General exposure to cosmetics: A list with missing data from the SCCS NoG should be made for the next meeting.
- NoG: the revision of the CMR chapter was discussed and the full exposure data of humans including biomonitoring data (if available) should be required, including data from other scientific bodies like ECHA. Each substance should be treated on a case by case basis.

6. ANY OTHER BUSINESS

Next meetings are planned on 8 July and 8 October.

Attendance list of participants from Cosmetics Europe:

- Dr Nathalie Alepée (L'Oréal), representative of Cosmetics Europe
- Dr Dagmar Bury (L'Oréal), representative of Cosmetics Europe
- Dr Patric Amcoff, Interim Director Science & Research, Cosmetics Europe